Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cordyceps cephalosporin powder is a natural product active pharmaceutical ingredient (API) developed and manufactured by Changxing Pharmaceutical. It is produced through the liquid deep fermentation of *Cephalosporium sinensis*, a fungal strain originally isolated from natural *Cordyceps sinensis*. The resulting powder contains a complex profile of bioactive compounds, including cordycepic acid, cordycepin, cordyceps polysaccharides, and various amino acids. This API serves as the primary raw material for several approved traditional Chinese medicine (TCM) formulations, most notably Ningxinbao and Zhiling capsules. It is clinically utilized to improve cardiac function and manage various heart rhythm disorders, such as arrhythmias, sinoatrial node dysfunction, and atrioventricular conduction blocks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cordyceps cephalosporin powder.